In a recent meta-analysis of HBsAg−/anti-HBc+ patients with rheumatoid arthritis receiving IL-6 inhibitor therapy, the pooled reactivation rate was found to be 0.0% (4 studies; 1 reactivation in 162 patients; I2, 0%; P, 0.43) [11]. Here, KRT88P is linked to rheumatoid arthritis.